

12 April 2022  
 ASX Code: MXC  
 LSE Code: MXC

## Lapse of Performance Rights, Directors 3Y's and new London based Chief Financial Officer

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company')** provides the accompanying Appendix 3Ys "Change in Director's Interest Notice" to inform the market of the recent change to directors' interests in the Company which resulted from the lapse of Performance Rights previously granted to the directors due to a vesting condition not being satisfied.

MGC Pharma would also like to advise that Mr Daniel Kendall has ceased in his role as Chief Financial Officer for the Company, with Mr Roby Zomer, the Company's Managing Director and CEO assuming the interim CFO role and responsibilities until a new CFO is appointed.

Due to the significant increase in the Company's European Union and Israeli manufacturing and research operations, the Company has determined that it is best served with a London based CFO to manage the financial and accounting operations of the rapidly growing MGC Pharma business.

Following the LSE dual listing in early 2021, a number of the corporate functions of the business have been transferred to London, with the soon to be appointed CFO, and the Company's Managing Director & CEO Roby Zomer to relocate there shortly.

The Board would like to wish Mr Kendall the best for his future endeavours.

--Ends--

**Authorised for release by the Executive Chairman, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
 CEO & Managing Director  
 +61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Broker – Turner Pope**

Andy Thacker  
 +44 203 657 0050  
[info@turnerpope.com](mailto:info@turnerpope.com)

**MGC Pharmaceuticals Ltd**

David Lim  
 Company Secretary  
 +61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK PR Advisors – Tavistock**

Charles Vivian / Tim Pearson  
 +44 207 920 3150  
[mgcpharma@tavistock.co.uk](mailto:mgcpharma@tavistock.co.uk)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Roby Reuven Zomer
<b>Date of last notice</b>	9 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Chitta Lu Limited (Director and sole shareholder) & HSBC Custody Nominees (Australia) Limited
<b>Date of change</b>	1. 14 October 2021 2. & 3. 6 April 2022
<b>No. of securities held prior to change</b>	<b>Chitta Lu Limited</b> 3,000,001 Fully Paid Ordinary Shares 5,000,000 Performance Rights 7,500,000 Performance Rights Class A expiring 1 April 2025 17,500,000 Performance Rights Class B expiring 1 April 2025 2,400,000 Performance Rights Class C expiring 30 June 2024  <b>HSBC Custody Nominees (Australia) Limited</b> 30,000,000 Fully Paid Ordinary Shares
<b>Class</b>	1. Fully Paid Ordinary Shares 2. Performance Rights 3. Performance Rights Class A expiring 1 April 2025

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Number acquired</b>	1. 3,000,000 transfer to HSBC Custodian holding account from Chitta Lu Ltd account
<b>Number disposed</b>	1. 3,000,000 transfer from Chitta Lu Ltd account to HSBC Custodian holding account 2. 2,500,000 3. 7,500,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	1. \$Nil – transfer between holding accounts 2. \$Nil – Lapse of Performance Rights 3. \$Nil – Lapse of Performance Rights
<b>No. of securities held after change</b>	<b>Chitta Lu Limited</b> 1 Fully Paid Ordinary Shares 2,500,000 Performance Rights 17,500,000 Performance Rights Class B expiring 1 April 2025 2,400,000 Performance Rights Class C expiring 30 June 2024  <b>HSBC Custody Nominees (Australia) Limited</b> 33,000,000 Fully Paid Ordinary Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1. Transfer between holding accounts 2 & 3. Lapse of Performance Rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Brett Anthony Mitchell
<b>Date of last notice</b>	9 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>Brett and Michelle Mitchell &lt;Mitchell Spring Family A/C&gt;</b> Trustee <b>Brett and Michelle Mitchell &lt;Lefthanders Super Fund A/C&gt;</b> Trustee
<b>Date of change</b>	1 & 2. 6 April 2022 3. 20 December 2020
<b>No. of securities held prior to change</b>	<b>Brett and Michelle Mitchell &lt;Mitchell Spring Family A/C&gt;</b> 22,542,221 Fully Paid Ordinary Shares 2,500,000 Performance Rights 17,500,000 Performance Rights Class B expiring 1 April 2025  <b>Brett and Michelle Mitchell &lt;Lefthanders Super Fund A/C&gt;</b> 8,418,337 Fully Paid Ordinary Shares 2,500,000 Performance Rights 7,500,000 Performance Rights Class A expiring 1 April 2025 2,400,000 Performance Rights Class C expiring 30 June 2024  <b>Chieftain Securities Pty Ltd</b> 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Class</b>	<ol style="list-style-type: none"> <li>1. Performance Rights</li> <li>2. Performance Rights Class A expiring 1 April 2025</li> <li>3. Unlisted Options</li> </ol>
<b>Number acquired</b>	<p>N/A</p> <ol style="list-style-type: none"> <li>3. Transfer of Unlisted options from Chieftain Securities Pty Ltd to YCAGAGF Investments Pty Ltd</li> </ol>
<b>Number disposed</b>	<p><b>Brett and Michelle Mitchell &lt;Mitchell Spring Family A/C&gt;:</b></p> <ol style="list-style-type: none"> <li>1. 1,250,000 Performance Rights</li> </ol> <p><b>Brett and Michelle Mitchell &lt;Lefthanders Super Fund A/C&gt;:</b></p> <ol style="list-style-type: none"> <li>1. 1,250,000 Performance Rights</li> <li>2. 7,500,000 Performance Rights Class A expiring 1 April 2025</li> <li>3. Transfer of Unlisted options from Chieftain Securities Pty Ltd to YCAGAGF Investments Pty Ltd</li> </ol>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<p><b>Brett and Michelle Mitchell &lt;Mitchell Spring Family A/C&gt;:</b></p> <ol style="list-style-type: none"> <li>1. Nil - Lapse of Performance Rights</li> </ol> <p><b>Brett and Michelle Mitchell &lt;Lefthanders Super Fund A/C&gt;:</b></p> <ol style="list-style-type: none"> <li>1. Nil - Lapse of Performance Rights</li> <li>2. Nil - Lapse of Performance Rights</li> <li>3. Nil - Transfer of Unlisted options from Chieftain Securities Pty Ltd to YCAGAGF Investments Pty Ltd. Mr Mitchell is a director and 33% shareholder of YCAGAGF Investments, there has been no change in beneficial interest in the options for Mr Mitchell on the entity transfer.</li> </ol>
<b>No. of securities held after change</b>	<p><b>Brett and Michelle Mitchell &lt;Mitchell Spring Family A/C&gt;</b></p> <p>22,542,221 Fully Paid Ordinary Shares 1,250,000 Performance Rights 17,500,000 Performance Rights Class B expiring 1 April 2025</p> <p><b>Brett and Michelle Mitchell &lt;Lefthanders Super Fund A/C&gt;</b></p> <p>8,418,337 Fully Paid Ordinary Shares 1,250,000 Performance Rights 2,400,000 Performance Rights Class C expiring 30 June 2024</p> <p><b>YCAGAGF Investments Pty Ltd (33% shareholding)</b></p> <p>1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> <li>1.- 2. Lapse of Performance Rights</li> <li>3. Transfer between related parties</li> </ol>

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Evan Hayes
<b>Date of last notice</b>	4 October 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct										
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.											
<b>Date of change</b>	6 April 2022										
<b>No. of securities held prior to change</b>	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="border-bottom: 1px solid black;"><u>Direct holding</u></td> <td></td> </tr> <tr> <td style="padding-left: 20px;">295,000</td> <td>Fully Paid Ordinary Shares</td> </tr> <tr> <td style="padding-left: 20px;">600,000</td> <td>Performance Rights Class A expiring 1 April 2025</td> </tr> <tr> <td style="padding-left: 20px;">1,400,000</td> <td>Performance Rights Class B expiring 1 April 2025</td> </tr> <tr> <td style="padding-left: 20px;">600,000</td> <td>Performance Rights Class C expiring 30 June 2024</td> </tr> </table>	<u>Direct holding</u>		295,000	Fully Paid Ordinary Shares	600,000	Performance Rights Class A expiring 1 April 2025	1,400,000	Performance Rights Class B expiring 1 April 2025	600,000	Performance Rights Class C expiring 30 June 2024
<u>Direct holding</u>											
295,000	Fully Paid Ordinary Shares										
600,000	Performance Rights Class A expiring 1 April 2025										
1,400,000	Performance Rights Class B expiring 1 April 2025										
600,000	Performance Rights Class C expiring 30 June 2024										
<b>Class</b>	Performance Rights Class A expiring 1 April 2025										
<b>Number acquired</b>	N/A										
<b>Number disposed</b>	600,000										
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$Nil										

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>No. of securities held after change</b>	Direct holding 295,000 Fully Paid Ordinary Shares 1,400,000 Performance Rights Class B expiring 1 April 2025 600,000 Performance Rights Class C expiring 30 June 2024
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Nativ Segev
<b>Date of last notice</b>	9 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Bright Global Limited (Director and sole shareholder) HSBC Custody Nominees (Australia) Limited (Beneficiary)
<b>Date of change</b>	6 April 2022
<b>No. of securities held prior to change</b>	<b>Direct:</b> 1 Fully Paid Ordinary Share  <b>Bright Global Limited:</b> 5,500,000 Fully Paid Ordinary Shares 450,000 Performance Rights Class A expiring 1 April 2025 1,050,000 Performance Rights Class B expiring 1 April 2025 600,000 Performance Rights Class C expiring 30 June 2024  <b>HSBC Custody Nominee (Australia) Limited:</b> 52,500,000 Fully Paid Ordinary Shares
<b>Class</b>	Performance Rights Class A expiring 1 April 2025
<b>Number acquired</b>	N/A

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	450,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$Nil
<b>No. of securities held after change</b>	<b>Direct:</b> 1   Fully Paid Ordinary Share  <b>Bright Global Limited:</b> 5,500,000   Fully Paid Ordinary Shares 1,050,000   Performance Rights Class B expiring 1 April 2025 600,000    Performance Rights Class C expiring 30 June 2024  <b>HSBC Custody Nominee (Australia) Limited:</b> 52,500,000   Fully Paid Ordinary Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
--	----

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ross Grant Thomas Walker
<b>Date of last notice</b>	9 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ross G T Walker Pty Ltd
<b>Date of change</b>	6 April 2022
<b>No. of securities held prior to change</b>	<b>Ross G T Walker Pty Ltd:</b> 4,970,370 Fully paid ordinary shares 450,000 Performance Rights Class A expiring 1 April 2025 1,050,000 Performance Rights Class B expiring 1 April 2025
<b>Class</b>	Performance Rights Class A expiring 1 April 2025
<b>Number acquired</b>	N/A
<b>Number disposed</b>	450,000 Performance Rights Class A expiring 1 April 2025
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$Nil

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>No. of securities held after change</b>	<b>Ross G T Walker Pty Ltd:</b> 4,970,370 Fully paid ordinary shares 1,050,000 Performance Rights Class B expiring 1 April 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Stephen Barry Parker
<b>Date of last notice</b>	7 October 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	1. <u>Direct</u> Mr Stephen Barry Parker  2. <u>Indirect</u> Held through a UK Individual Savings Account ("ISA") Registered Holder is Barclays Bank PLC
<b>Date of change</b>	6 April 2022
<b>No. of securities held prior to change</b>	1. <u>Direct holding</u> Mr Stephen Barry Parker 600,000 Fully Paid Ordinary Shares 600,000 Performance Rights Class A expiring 1 April 2025 1,400,000 Performance Rights Class B expiring 1 April 2025  2. <u>Indirect holding</u> Barclays Bank PLC 282,316 Fully Paid Ordinary Shares
<b>Class</b>	Performance Rights Class A expiring 1 April 2025
<b>Number acquired</b>	N/A

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Number disposed</b>	600,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$Nil
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. <u>Direct holding</u> Mr Stephen Barry Parker 600,000 Fully Paid Ordinary Shares 1,400,000 Performance Rights Class B expiring 1 April 2025</li> <li>2. <u>Indirect holding</u> Barclays Bank PLC 282,316 Fully Paid Ordinary Shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

*Rule 3.19A.2*

+ See chapter 19 for defined terms.